Related Experiment Video
Updated: Jun 4, 2025

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
Abstract:
Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for patients with this disease. While androgens are widely appreciated to enhance anabolic metabolism, how SPA-mediated metabolic changes alter prostate cancer progression and therapy response is unknown. Here, we report that SPA markedly increased intracellular and secreted polyamines in prostate cancer models. This occurred through AR binding at enhancer sites upstream of the ODC1 promoter to increase abundance of ornithine decarboxylase (ODC), a rate-limiting enzyme of polyamine synthesis, and de novo synthesis of polyamines from arginine. SPA-stimulated polyamines enhance prostate cancer fitness, as dCas9-KRAB-mediated inhibition of AR regulation of ODC1 or direct ODC inhibition by difluoromethylornithine (DFMO) increased efficacy of SPA. Mechanistically, this occurred in part due to increased activity of S-adenosylmethionine decarboxylase 1 (AMD1), which was stimulated both by AR and by loss of negative feedback by polyamines, leading to depletion of its substrate S-adenosylmethionine and global protein methylation. These data provided the rationale for a clinical trial testing the safety and efficacy of BAT in combination with DFMO for patients with metastatic castration-resistant prostate cancer. Pharmacodynamic studies of this drug combination in the first five patients on trial indicated that the drug combination resulted in effective polyamine depletion in plasma. Thus, the AR potently stimulates polyamine synthesis, which constitutes a vulnerability in prostate cancer treated with SPA that can be targeted therapeutically.
Insights
Supraphysiological androgens (SPA) boost polyamine synthesis in prostate cancer by activating the androgen receptor (AR) to regulate ODC1. Inhibiting polyamine synthesis enhances SPA efficacy, revealing a therapeutic vulnerability.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Pathways
Background:
- Supraphysiological androgen (SPA) treatment, including Bipolar Androgen Therapy (BAT), paradoxically inhibits castration-resistant prostate cancer (CRPC) growth in AR-active tumors.
- The metabolic alterations induced by SPA and their impact on CRPC progression and therapeutic response remain poorly understood.
Purpose of the Study:
- To investigate the metabolic changes, specifically polyamine synthesis, induced by SPA in prostate cancer models.
- To elucidate the mechanism by which SPA influences polyamine metabolism and its role in CRPC progression.
- To evaluate the therapeutic potential of targeting polyamine synthesis in combination with SPA.
Main Methods:
- Utilized prostate cancer models to assess the impact of SPA on intracellular and secreted polyamines.
- Investigated the role of androgen receptor (AR) binding to enhancer sites upstream of the Ornithine Decarboxylase 1 (ODC1) promoter.
- Employed dCas9-KRAB-mediated inhibition of AR regulation and difluoromethylornithine (DFMO) to inhibit ODC activity.
- Assessed the effects of polyamine depletion on S-adenosylmethionine decarboxylase 1 (AMD1) activity and global protein methylation.
- Conducted a Phase I clinical trial combining BAT and DFMO in metastatic CRPC patients, including pharmacodynamic studies.
Main Results:
- SPA significantly increased intracellular and secreted polyamines in prostate cancer models.
- AR binding at enhancer sites increased ODC1 abundance, driving de novo polyamine synthesis from arginine.
- Inhibition of AR-driven ODC1 or ODC activity with DFMO enhanced the efficacy of SPA treatment.
- SPA increased AMD1 activity, partly due to AR stimulation and reduced polyamine feedback, leading to S-adenosylmethionine depletion and decreased global protein methylation.
- Pharmacodynamic studies in patients showed effective plasma polyamine depletion with the BAT + DFMO combination.
Conclusions:
- Androgen receptor (AR) potently stimulates polyamine synthesis in prostate cancer.
- SPA-induced polyamine synthesis represents a critical metabolic vulnerability in AR-driven prostate cancer.
- Targeting polyamine synthesis, for example with DFMO, in combination with SPA (BAT) offers a promising therapeutic strategy for metastatic CRPC.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Internal Receptors
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Drugs Affecting Neurotransmitter Synthesis
Biosynthesis of Nucleic Acids
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...